As GlaxoSmithKline plc Nears A 52-Week Low, Is It Time To Buy?

Is now the time to buy GlaxoSmithKline plc (LON: GSK) or should you stay away?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2015 is shaping up to be a pretty terrible year for GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). Year to date, the company’s shares have hardly budged while the rest of the FTSE All World Pharma & Biotech sector has risen by 10%. 

And now Glaxo’s shares are closing in on their 52-week low of 1,296p, after falling by 14% during the past 12 months.

But should investors look to buy on this weakness or could Glaxo’s shares fall further? 

Investor concern 

Investors have turned their back on Glaxo during the past 12 months for several reasons.

Firstly, there’s been plenty of speculation that the company is contemplating a dividend cut. As a result, investors have been selling up and searching for a safer yield elsewhere. 

Secondly, there’s been some concern about Glaxo’s new business strategy. In particular, the group has recently reduced its dependence on the lucrative pharmaceutical market by increasing investment in the slow-and-steady vaccines and consumer healthcare market.

For example, a $20bn asset swap with Novartis last year saw Glaxo trade its lucrative cancer drug portfolio for vaccines and consumer healthcare assets.

Management targets

Investors’ concerns regarding Glaxo’s change of strategy and dividend sustainability are well founded.

However, the company’s management has recently come out to dispel these worries. 

It’s expected that Glaxo’s core earnings per share will decline by 15% this year. But from 2016 to 2020, group revenue is expected to grow at a compound annual growth rate of “low-to-mid single digits”. What’s more, over the same period, core earnings per share are expected to expand at a rate in the “mid-to-high single digits”.

Cost savings will help the group maintain its dividend payout. Glaxo’s management has stated that a per-share payout of at least 80p is guaranteed for the next three years. 

At present levels, a payout of 80p per share translates into a dividend yield of 5.9%. 

Impressive pipeline 

Concerns over Glaxo’s business strategy also seem to be overdone. Glaxo has had more drugs approved by regulators than any other pharmaceutical company over the last five years. And this trend is set to continue. 

City analysts who specialise in the pharmaceutical sector have commended Glaxo’s treatment pipeline, rating it as one of the best in the business. Glaxo’s R&D spending currently amounts to £3.5bn per annum. 

Also, Glaxo is hunting out the best joint-venture opportunities in the market.

This week the company announced the launch of three early-stage biotech companies jointly funded with Avalon Ventures, a US investment firm. 

The bottom line 

Overall, Glaxo looks to be a classic contrarian buy after recent declines.

The company’s dividend appears to be safe for the next three years, and while earnings are set to contract this year, steady growth is predicted through to the end of the decade.

For long-term investors who are prepared to wait, and take home an attractive 5.9% dividend yield, Glaxo could be a great buy. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »